Brazil’s health authorities are monitoring two patients for Ebola, prompting British health officials to ready contingency measures. The news, while alarming on the surface, has been met with a collective shrug from financial markets, which are far more preoccupied with inflation data and central bank positioning than a potential outbreak in South America.
Let’s be clear: this is not a repeat of 2014. The global health infrastructure is better prepared, and Brazil’s surveillance systems have been upgraded since the Zika crisis. Still, the psychological impact on an already jittery market cannot be dismissed entirely. If these cases are confirmed, we can expect a flight to safety, with gilt yields compressing and the dollar strengthening against the real. But for now, the reaction is muted. The VIX is barely twitching.
The real risk here is not the virus itself but the sovereign exposure. Brazil is already walking a fiscal tightrope, with a primary deficit that would make even the most ardent Keynesian blush. An Ebola outbreak would hammer tourism, disrupt supply chains, and force the central bank to choose between fighting inflation and stimulating growth. That is a lose-lose scenario.
For British investors, the exposure is limited. UK-based funds hold less than 2% of their emerging market allocations in Brazil. But the secondary effects matter. A Brazil slowdown would hit commodity prices, particularly iron ore and soy, which would ripple through miners like Rio Tinto and Glencore. The FTSE 100 has a heavy mining weighting, so that is the channel to watch.
As for the health response, the UK’s NHS is on standby, which is prudent but also a reminder of the public finance cost. The Treasury already has its hands full with the gilt market demanding higher yields as inflation expectations remain sticky. The last thing the Chancellor needs is an emergency health budget.
In the meantime, watch the Brazilian real and the iShares Brazil ETF. If the cases are confirmed, I would expect capital flight to accelerate. The carry trade in the real has been a popular play for yield-hungry investors, but that trade will unwind fast if the outbreak materialises.
For now, though, it is a watch-and-wait situation. The market’s indifference is rational, based on the low probability of a widespread epidemic. But as any epidemiologist will tell you, tails can be fat. And in financial markets, fat tails are where fortunes are lost.
My advice: tighten stop-losses on Brazilian exposure and keep a close eye on the daily case count. If it rises, cut and run. If it doesn’t, the yield pickup will remain attractive. But remember, in the game of contagion, the house always wins eventually.
